• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种针对 CD19 和 CD33 的单链三聚体通过双重靶向介导混合谱系白血病细胞的有效裂解。

A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting.

机构信息

Department of Biology, University of Erlangen-Nuremberg, Erlangen, Germany.

出版信息

MAbs. 2011 Jan-Feb;3(1):21-30. doi: 10.4161/mabs.3.1.14057. Epub 2011 Jan 1.

DOI:10.4161/mabs.3.1.14057
PMID:21081841
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3038008/
Abstract

A single-chain triplebody (sctb) 33-ds16-ds19 comprising two distal single-chain Fv fragments (scFvs) specific for the lymphoid antigen CD19 and the myeloid antigen CD33 flanking a central scFv specific for CD16, which is the low affinity Fc-receptor (FcγRIII) present on natural killer cells and macrophages, was produced and its properties were investigated. CD33 and CD19 in combination are present on acute leukemiablasts with mixed lineage phenotype, but not on normal human hematopoietic cells. For comparison, two bispecific scFvs (bsscFvs), ds19-ds16 and 33-ds16, with monovalent binding to CD19 and CD33, respectively, were also studied. The sctb 33-ds16-ds19 specifically interacted with all 3 antigens. On the antigen double-positive cell line BV-173, the sctb bound with 2-fold greater avidity than bsscFv ds19-ds16 (KD = 21 vs. 42 nM) and with 1.4-fold greater avidity than bsscFv 33-ds16 (KD = 29 nM). All 3 fusion proteins had similar affinity for CD16 and sufficient thermic stability in human serum. In antibody-dependent cellular cytotoxicity (ADCC) reactions with human mononuclear cells as effectors, the sctb promoted lysis of BV-173 cells at 23-fold lower concentrations than bsscFv ds19-ds16 and at 1.4-fold lower concentrations than bsscFv 33-ds16. The sctb also mediated potent ADCC of the antigen double-positive mixed lineage leukemia cell line SEM, and the half-maximal concentration EC50 for BV-173 cells was 7 pM. Therefore, CD19 and CD33 are present on the surface of these leukemic cell lines such that they can be connected by a single sctb molecule, permitting the recruitment of NK cells via CD16 and tumor cell lysis.

摘要

一种由两个针对淋巴细胞抗原 CD19 和髓样抗原 CD33 的远端单链 Fv 片段(scFv)组成的单链三聚体(sctb)33-ds16-ds19,夹在一个针对 CD16 的中央 scFv 之间,CD16 是自然杀伤细胞和巨噬细胞上的低亲和力 Fc 受体(FcγRIII),该 sctb 被生产出来并研究了其性质。CD33 和 CD19 同时存在于具有混合谱系表型的急性白血病blasts 中,但不存在于正常的人类造血细胞中。为了比较,还研究了两种单价结合 CD19 和 CD33 的双特异性 scFv(bsscFv)ds19-ds16 和 33-ds16。sctb 33-ds16-ds19 特异性地与所有 3 种抗原相互作用。在抗原双阳性细胞系 BV-173 上,sctb 的结合亲和力比 bsscFv ds19-ds16 高 2 倍(KD = 21 对 42 nM),比 bsscFv 33-ds16 高 1.4 倍(KD = 29 nM)。所有 3 种融合蛋白对 CD16 的亲和力相似,在人血清中有足够的热稳定性。在以人单核细胞为效应物的抗体依赖性细胞毒性(ADCC)反应中,sctb 促进 BV-173 细胞的裂解,浓度比 bsscFv ds19-ds16 低 23 倍,比 bsscFv 33-ds16 低 1.4 倍。sctb 还介导抗原双阳性混合谱系白血病细胞系 SEM 的有效 ADCC,BV-173 细胞的半最大浓度 EC50 为 7 pM。因此,CD19 和 CD33 存在于这些白血病细胞系的表面,使得它们可以通过单个 sctb 分子连接,通过 CD16 募集 NK 细胞并裂解肿瘤细胞。

相似文献

1
A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting.一种针对 CD19 和 CD33 的单链三聚体通过双重靶向介导混合谱系白血病细胞的有效裂解。
MAbs. 2011 Jan-Feb;3(1):21-30. doi: 10.4161/mabs.3.1.14057. Epub 2011 Jan 1.
2
A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting.一种针对 CD19 和 HLA-DR 的重组三联体通过双靶向作用介导对抗原双阳性细胞的优先结合。
MAbs. 2012 Jan-Feb;4(1):45-56. doi: 10.4161/mabs.4.1.18498.
3
Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16.通过针对 CD33 和 CD16 的双特异性抗体衍生物有效清除急性髓性白血病细胞。
J Immunother. 2010 Jul-Aug;33(6):599-608. doi: 10.1097/CJI.0b013e3181dda225.
4
A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.一种新型的针对CD19的重组双特异性抗体衍生物,对人白血病细胞具有增强的免疫效应功能。
J Immunother. 2008 Nov-Dec;31(9):871-84. doi: 10.1097/CJI.0b013e318186c8b4.
5
A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells.一种双靶向三聚体介导了对抗原双阳性白血病细胞的优先重定向裂解,而不是单阳性白血病细胞。
MAbs. 2014 Jan-Feb;6(1):286-96. doi: 10.4161/mabs.26768.
6
A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting.一种针对 CD123 和 CD33 的重组三特异性单链 Fv 衍生物通过双重靶向介导急性髓系白血病细胞的有效清除。
Br J Haematol. 2010 Sep;150(5):574-86. doi: 10.1111/j.1365-2141.2010.08300.x. Epub 2010 Jul 16.
7
Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells.针对 CD19 和 CD16 的异二聚体双特异性抗体衍生物可诱导针对 B 淋巴细胞肿瘤细胞的有效抗体依赖性细胞细胞毒性。
Cancer Lett. 2011 Apr 28;303(2):128-39. doi: 10.1016/j.canlet.2011.01.020. Epub 2011 Feb 19.
8
Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells.双靶点三体33-3-19介导双表型CD19+CD33+白血病细胞的选择性裂解。
Oncotarget. 2016 Apr 19;7(16):22579-89. doi: 10.18632/oncotarget.8022.
9
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.一种四价双特异性串联抗体(CD19/CD3)AFM11能够有效募集T细胞,从而有力地裂解CD19(+)肿瘤细胞。
MAbs. 2015;7(3):584-604. doi: 10.1080/19420862.2015.1029216.
10
Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).用一种针对CD19和FcγRIII(CD16)的稳定双特异性单链Fv抗体有效裂解淋巴瘤细胞。
Br J Haematol. 2005 Jul;130(2):218-28. doi: 10.1111/j.1365-2141.2005.05414.x.

引用本文的文献

1
Potent Apoptosis Induction by a Novel Trispecific B7-H3xCD16xTIGIT 2+1 Common Light Chain Natural Killer Cell Engager.新型三特异性B7-H3xCD16xTIGIT 2+1共轻链自然杀伤细胞衔接器强力诱导细胞凋亡
Molecules. 2024 Mar 4;29(5):1140. doi: 10.3390/molecules29051140.
2
When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy.当三不是一群人时:用于增强癌症免疫疗法的三特异性抗体。
Theranostics. 2023 Jan 22;13(3):1028-1041. doi: 10.7150/thno.81494. eCollection 2023.
3
Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer.三特异性 T 细胞衔接器用于结直肠癌的双重肿瘤靶向。
Oncoimmunology. 2022 Feb 7;11(1):2034355. doi: 10.1080/2162402X.2022.2034355. eCollection 2022.
4
Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future.自然杀伤细胞疗法治疗血液系统恶性肿瘤:成功、挑战与未来。
Stem Cell Res Ther. 2021 Mar 25;12(1):211. doi: 10.1186/s13287-021-02277-x.
5
A CRISPR Screen Reveals Resistance Mechanisms to CD3-Bispecific Antibody Therapy.CRISPR 筛选揭示了对 CD3 双特异性抗体治疗的耐药机制。
Cancer Immunol Res. 2021 Jan;9(1):34-49. doi: 10.1158/2326-6066.CIR-20-0080. Epub 2020 Nov 11.
6
Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions.双特异性抗体治疗多发性骨髓瘤:靶点、药物、临床试验及未来方向的综述。
Front Immunol. 2020 Apr 24;11:501. doi: 10.3389/fimmu.2020.00501. eCollection 2020.
7
Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?迎接癌症免疫治疗挑战:双特异性抗体,前行之路?
Antibodies (Basel). 2015 Dec 26;5(1):1. doi: 10.3390/antib5010001.
8
Natural Killer Cells as Key Players of Tumor Progression and Angiogenesis: Old and Novel Tools to Divert Their Pro-Tumor Activities into Potent Anti-Tumor Effects.自然杀伤细胞作为肿瘤进展和血管生成的关键参与者:将其促肿瘤活性转变为强大抗肿瘤效应的新旧工具
Cancers (Basel). 2019 Apr 1;11(4):461. doi: 10.3390/cancers11040461.
9
Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset.三体介导白细胞介素-2激活的供体自然杀伤(NK)细胞增强抗白血病反应性,并损害其表达CD33的NK亚群的活力。
Front Immunol. 2017 Sep 8;8:1100. doi: 10.3389/fimmu.2017.01100. eCollection 2017.
10
Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.自然杀伤细胞被释放:检查点受体阻断和 BiKE/TriKE 在 NK 介导的抗肿瘤免疫治疗中的利用。
Semin Immunol. 2017 Jun;31:64-75. doi: 10.1016/j.smim.2017.07.011. Epub 2017 Sep 5.

本文引用的文献

1
A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting.一种针对 CD123 和 CD33 的重组三特异性单链 Fv 衍生物通过双重靶向介导急性髓系白血病细胞的有效清除。
Br J Haematol. 2010 Sep;150(5):574-86. doi: 10.1111/j.1365-2141.2010.08300.x. Epub 2010 Jul 16.
2
Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16.通过针对 CD33 和 CD16 的双特异性抗体衍生物有效清除急性髓性白血病细胞。
J Immunother. 2010 Jul-Aug;33(6):599-608. doi: 10.1097/CJI.0b013e3181dda225.
3
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.三功能抗体 catumaxomab 治疗上皮癌恶性腹水:前瞻性随机 2/3 期试验结果。
Int J Cancer. 2010 Nov 1;127(9):2209-21. doi: 10.1002/ijc.25423.
4
Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence.连续静脉输注阿仑单抗联合皮下注射利妥昔单抗治疗慢性淋巴细胞白血病复发。
Cancer. 2010 May 15;116(10):2360-5. doi: 10.1002/cncr.24958.
5
TCR and Lat are expressed on separate protein islands on T cell membranes and concatenate during activation.T 细胞受体 (TCR) 和 Lat 在 T 细胞膜上的独立蛋白岛上表达,并在激活过程中串联。
Nat Immunol. 2010 Jan;11(1):90-6. doi: 10.1038/ni.1832. Epub 2009 Dec 13.
6
Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study.挽救性治疗联合吉妥珠单抗奥唑米星治疗初治或二次复发急性髓系白血病患儿:一项 II 期研究的结果。
Br J Haematol. 2010 Mar;148(5):768-76. doi: 10.1111/j.1365-2141.2009.08011.x. Epub 2009 Dec 8.
7
Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia.人类混合谱系白血病中编码干细胞调节因子的基因处的异常染色质。
Genes Dev. 2008 Dec 15;22(24):3403-8. doi: 10.1101/gad.1741408.
8
Chromosomal rearrangements leading to MLL gene fusions: clinical and biological aspects.导致MLL基因融合的染色体重排:临床与生物学方面
Cancer Res. 2008 Dec 15;68(24):10024-7. doi: 10.1158/0008-5472.CAN-08-2208.
9
A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.一种新型的针对CD19的重组双特异性抗体衍生物,对人白血病细胞具有增强的免疫效应功能。
J Immunother. 2008 Nov-Dec;31(9):871-84. doi: 10.1097/CJI.0b013e318186c8b4.
10
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.极低剂量的T细胞结合抗体使癌症患者肿瘤消退。
Science. 2008 Aug 15;321(5891):974-7. doi: 10.1126/science.1158545.